BioCryst Pharmaceuticals gets grant for inhibitors of the complement system for disease treatment
According to GlobalData’s company profile on BioCryst Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. BioCryst Pharmaceuticals's grant share as of February 2024 was 37%. Grant share is based on the ratio …